Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study

Protagonist Therapeutics

10/03/2025 13:38

** Drug developer Protagonist Therapeutics' PTGX.O shares rise 30.4% to $50.02

** PTGX says the mid-stage study of all three doses of once-daily experimental drug, icotrokinra, conducted by its collaboration partner Johnson & Johnson JNJ.N met its main goal in patients with ulcerative colitis

** Ulcerative colitis, a form of inflammatory bowel disease (IBD), is a condition in which the lining of the large intestine (colon) and rectum become inflamed

** Co says the study showed significant improvements over placebo in clinical recovery, symptom relief, and showed reduction in signs of disease severity within 12 weeks

** Co says the study achieved a response rate of 63.5% vs 27% for placebo

** PTGX had risen 24.2% in the past 12 months, as of last close

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))